Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: A pooled analysis of randomised, double-blind, placebo-controlled trials

Alimentary Pharmacology and Therapeutics

Volumn 39, Issue 10, 2014, Pages 1161-1168

  Schoenfeld, P ^a   Pimentel, M ^b   Chang, L ^c   Lembo, A ^d   Chey, W D ^a   Yu, J ^e   Paterson, C ^e   Bortey, E ^e   Forbes, W P ^e  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^e Salix a Division of Valeant Pharmaceuticals North America LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; RIFAXIMIN;

ABDOMINAL PAIN; ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; BACKACHE; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEADACHE; HUMAN; IRRITABLE COLON; MAJOR CLINICAL STUDY; MALE; NAUSEA; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; RISK ASSESSMENT; SINUSITIS; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VOMITING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL AGENTS; HUMANS; IRRITABLE BOWEL SYNDROME; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RIFAMYCINS; YOUNG ADULT;

EID: 84899114664     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12735     Document Type: Article

References (31)

1. Brandt LJ, Chey WD, Foxx-Orenstein AE, et al,. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol 2009; 104 (Suppl. 1): S1-35.
2. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC,. Functional bowel disorders. Gastroenterology 2006; 130: 1480-91.
3. Shah E, Kim S, Chong K, Lembo A, Pimentel M,. Evaluation of harm in the pharmacotherapy of irritable bowel syndrome. Am J Med 2012; 125: 381-93.
4. Tack J,. Antibiotic therapy for the irritable bowel syndrome. N Engl J Med 2011; 364: 81-2.
5. Menees SB, Maneerattannaporn M, Kim HM, Chey WD,. The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol 2012; 107: 28-35.
6. Adachi JA, DuPont HL,. Rifaximin: a novel nonabsorbed rifamycin for gastrointestinal disorders. Clin Infect Dis 2006; 42: 541-7.
7. Basseri RJ, Weitsman S, Barlow GM, Pimentel M,. Antibiotics for the treatment of irritable bowel syndrome. Gastroenterol Hepatol (NY) 2011; 7: 455-93.
8. Xifaxan (rifaximin) tablets [package insert]. Raleigh, NC: Salix Pharmaceuticals, Inc., 2012.
9. Pimentel M, Lembo A, Chey WD, et al,. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 2011; 364: 22-32.
10. Lembo A, Zakko SF, Ferreira NL, et al,. Rifaximin for the treatment of diarrhea-associated irritable bowel syndrome: short term treatment leading to long term sustained response. Gastroenterology 2008; 134: A-545.
11. ClinicalTrials.gov. Study to assess the efficacy and safety of rifaximin administered BID in the treatment of patients with diarrhea-associated irritable bowel syndrome. Clinicaltrials.gov. December 21, 2009. Available at: http://www.clinicaltrials.gov/ct2/show/NCT00269412?term=rifaximin+IBS&rank= 9. Accessed January 15, 2013.
12. Meyrat P, Safroneeva E, Schoepfer AM,. Rifaximin treatment for the irritable bowel syndrome with a positive lactulose hydrogen breath test improves symptoms for at least 3 months. Aliment Pharmacol Ther 2012; 36: 1084-93.
13. Peralta S, Cottone C, Doveri T, Almasio PL, Craxi A,. Small intestine bacterial overgrowth and irritable bowel syndrome-related symptoms: experience with rifaximin. World J Gastroenterol 2009; 15: 2628-31.
14. Esposito I, de Leon A, Di Gregorio G, et al,. Breath test for differential diagnosis between small intestinal bacterial overgrowth and irritable bowel disease: an observation on non-absorbable antibiotics. World J Gastroenterol 2007; 13: 6016-21.
15. Majewski M, McCallum RW,. Results of small intestinal bacterial overgrowth testing in irritable bowel syndrome patients: clinical profiles and effects of antibiotic trial. Adv Med Sci 2007; 52: 139-42.
16. Lessa FC, Gould CV, McDonald LC,. Current status of Clostridium difficile infection epidemiology. Clin Infect Dis 2012; 55 (Suppl. 2): S65-70.
17. Prantera C, Lochs H, Grimaldi M, Danese S, Scribano ML, Gionchetti P,. Rifaximin-extended intestinal release induces remission in patients with moderately active Crohn's disease. Gastroenterology 2012; 142: 473-81.
18. Bass NM, Mullen KD, Sanyal A, et al,. Rifaximin treatment in hepatic encephalopathy. N Engl J Med 2010; 362: 1071-81.
19. ® (Rifaximin) Tablets, 550 Mg, NDA 21-361: Briefing Document for Gastrointestinal Drugs Advisory Committee Meeting, 16 November 2011. Silver Springs, MD: U.S. Department of Health & Human Services; U.S. Food and Drug Administration, 2011. Available at: http://www.fda.gov/downloads/advisorycommittees/ committeesmeetingmaterials/drugs/gastrointestinaldrugsadvisorycommittee/ ucm279646.pdf. Accessed January 14, 2013.
20. Sanyal A, Mullen KD, Bass NM, et al,. Rates of commonly occurring infections in cirrhosis patients remain stable during long-term rifaximin treatment. J Hepatol 2012; 56: S255-6.
21. Shah D, Dang MD, Hasbun R, et al,. Clostridium difficile infection: update on emerging antibiotic treatment options and antibiotic resistance. Expert Rev Anti Infect Ther 2010; 8: 555-64.
22. Venugopal AA, Johnson S,. Current state of Clostridium difficile treatment options. Clin Infect Dis 2012; 55: S71-6.
23. Mattila E, Arkkila P, Mattila PS, Tarkka E, Tissari P, Anttila VJ,. Rifaximin in the treatment of recurrent Clostridium difficile infection. Aliment Pharmacol Ther 2013; 37: 122-8.
24. Garey KW, Ghantoji SS, Shah DN, et al,. A randomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection. J Antimicrob Chemother 2011; 66: 2850-5.
25. Rubin DT, Sohi S, Glathar M, Thomas T, Yadron N, Surma BL,. Rifaximin is effective for the treatment of Clostridium difficile-associated diarrhea: results of an open-label pilot study. Gastroenterol Res Pract 2011; 2011: 106978.
26. Basu PP, Dinani A, Rayapudi K, et al,. Rifaximin therapy for metronidazole-unresponsive Clostridium difficile infection: a prospective pilot trial. Therap Adv Gastroenterol 2010; 3: 221-5.
27. Scarpignato C, Pelosini I,. Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential. Chemotherapy 2005; 51 (Suppl. 1): 36-66.
28. De Leo C, Eftimiadi C, Schito GC,. Rapid disappearance from the intestinal tract of bacteria resistant to rifaximin. Drugs Exp Clin Res 1986; 12: 979-81.
29. DuPont HL, Jiang ZD,. Influence of rifaximin treatment on the susceptibility of intestinal Gram-negative flora and enterococci. Clin Microbiol Infect 2004; 10: 1009-11.
30. Kothary V, Scherl EJ, Bosworth B, et al,. Rifaximin resistance in Escherichia coli associated with inflammatory bowel disease correlates with prior rifaximin use, mutations in rpoB, and activity of PAbN-inhibitable efflux pumps. Antimicrob Agents Chemother 2013; 57: 811-7.
31. Carman RJ, Boone JH, Grover H, Wickham KN, Chen L,. In vivo selection of rifamycin-resistant Clostridium difficile during rifaximin therapy. Antimicrob Agents Chemother 2012; 56: 6019-20.